DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 Rozzell Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 Rozzell Et Al US 20060275279A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 ROZZell et al. (43) Pub. Date: Dec. 7, 2006 (54) METHODS FOR DISSOLVING CYSTINE (22) Filed: Jun. 6, 2005 STONES AND REDUCING CYSTINE IN URINE Publication Classification (76) Inventors: J. David Rozzell, Burbank, CA (US); (51) Int. Cl. Kavitha Vedha-Peters, Pasadena, CA A6II 38MSI (2006.01) (US) (52) U.S. Cl. ............................................................ 424/94.5 Correspondence Address: CHRISTIE, PARKER & HALE, LLP (57) ABSTRACT PO BOX 7O68 PASADENA, CA 91109–7068 (US) The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase (21) Appl. No.: 11/146,551 to increase the rate of cystine Stone dissolution. Patent Application Publication Dec. 7, 2006 Sheet 1 of 4 US 2006/0275279 A1 Hs1N1 Ncoh L-Homocysteine -- H2 O HOC n1ns 1-1N CO2H Cystathionine?3-lyase ls CO2H H2 Pyruvate L-Cystathionine H NH FIG. 1. Metabolic Reaction Catalyzed by Cystathionine-?s-Lyase Patent Application Publication Dec. 7, 2006 Sheet 2 of 4 US 2006/0275279 A1 NH2 Hs1 S Y1Ncoh L-Thiocysteine -- NH2 O Hozen-1- 1N1 no H Cystathionine e i 2 B-lyase CO2H NH2 P L-CystineA- y ruvate -- NH FIG. 2. "Un-Natural" Reaction Catalyzed by Cystathionine-?s-Lyase on L-Cystine Patent Application Publication Dec. 7, 2006 Sheet 3 of 4 US 2006/0275279 A1 Dissolution of Cystine Stones with Cystathionine beta-lyase (MetC) s -o-control (no MetC) al -H 1 mg/mL MetC g - 5 mg/mL MetC 3. -- 10 mg/mL MetC S. 1.5 Time (day) FIG. 3 Patent Application Publication Dec. 7, 2006 Sheet 4 of 4 US 2006/0275279 A1 10mg/mL Met C 5mg/mL Met C 1 mg/mL Met C 10mg/mL Met C 5mg/mL MetC" no enzyme O Stone no Stone control FIG. 4 US 2006/0275.279 A1 Dec. 7, 2006 METHODS FOR DISSOLVING CYSTINE STONES 0006. One of the most common methods for the removal AND REDUCING CYSTINE IN URINE of cystine Stones is percutaneous nephrolithotomy, in which a keyhole incision is made in the back and a nephroscope is BACKGROUND used to break up and remove the stones. Although this 0001. The cause of cystinuria, a genetic disease, is well procedure is less invasive than open Surgery, regular or understood. In healthy individuals, cystine is filtered from spinal anesthesia is normally required along with a hospital blood at the renal glomeruli and reabsorbed by the proximal stay of 2 to 3 days and a recovery time of a few weeks, in renal tubule cells via a transporter protein assembly that is which the patient may not be able to work (Ng and Streem, specialized for certain amino acids including cystine, argi 2001). nine, lysine, ornithine and citruline. In cystinurics this amino acid transporter assembly is defective, and cystine is 0007 An additional method for the treatment of cystine not reabsorbed normally. The cystine accumulates in the stones, which is a non-Surgical and minimally invasive urine in abnormally large amounts and, due to its insolubility route, involves the delivery of chemical solutions to the relative to other amino acids, crystallizes to produce stones. kidneys via a nephrostomy catheter for the chemical disso lution of the stones, also known as chemodissolution. A 0002 Cystinuria causes one of the most dangerous types variety of chemolytic agents have been used in this tech of kidney Stones, and cystinurics often experience a life of nique including Sodium bicarbonate and the organic buffer misery due to frequent Stone formation episodes. Cystine tris-hydroxymethylene-aminomethane (tromethamine-E) at stones are far more serious than the common calcium pH 10, both which act to provide a strongly alkaline envi oxalate stone because they can be over twenty-times larger ronment to dissolve the cystine Stones. Acetylcysteine is also than oxalate stones in weight and size. Cystine Stone formers frequently used in chemodissolution and dissolves the experience severe pain and frequently require emergency stones in a manner similar to D-penicillamine and Thiola by room visits, hospitalizations, and Surgeries. Current treat breaking the cystine disulfide and forming more soluble ment regimens for cystine Stones are often difficult and disulfides. However, this dissolution method has a limited unsuccessful. As a result, renal failure that results in a need role in the treatment of cystine Stones because these for dialysis or kidney transplantation is not uncommon. chemolytic agents perform extremely slowly and can typi Since no highly effective treatments for cystine stones exist, cally take weeks to months to dissolve stones (Ng and cystinurics face extremely difficult living circumstances, and the costs of cystinuria to the medical system are high, Streem, 2001). despite the low patient population (Beaudet, 1995). 0008 Given the drawbacks of the current methods for the treatment of cystine Stones, a minimally invasive, non 0003) Given the severity of the symptoms of cystinuria, Surgical route for treatment in which the cystinuric is treated treatment is essential. The first course of treatment usually under general anesthesia and in outpatient care would be involves management of urinary cystine levels to reduce the highly desirable. Chemodissolution possess these desirable risk of stone formation. These management methods include characteristics, however the slow rate of dissolution using Substantially increasing the intake of water (thereby increas the current chemical Solutions makes this an unfeasible ing the urine Volume and the amount of cystine that can be treatment. solubilized), dietary restrictions of methionine, which is a metabolic precursor of cystine, and Sodium, and oral admin 0009. The present invention overcomes this major draw istration of potassium citrate to increase the pH of the urine, back of chemodissolution by utilizing the catalytic ability of thereby increasing the solubility of cystine. When these an enzyme to increase the rate of cystine Stone dissolution to methods are ineffective, drug therapy is often used. provide an improved method of treatment. 0004 Drug therapy involves the use of thiol-containing SUMMARY OF THE INVENTION drugs, such as D-penicillamine, C.-mercaptopropionylgly 0010. One embodiment of the present invention is cine (Thiola), and captopril, to break the cystine disulfide directed to a method for dissolving cystine Stones, compris bond and form more soluble mixed disulfides. However, these drugs frequently give the patient various unpleasant ing the step of administering to a patient in need thereof a side effects such as gastrointestinal intolerance, rash and therapeutically effective amount of a cystinase. pain in the joints (Sakhaee and Sutton, 1996). These man 0011) Another embodiment of the present invention is agement techniques for cystinuric patients are often not directed to a method for the treatment of cystinuria, com Successful; one study saw 14 of 16 patients, who were using prising administering to a patient in need thereof a thera these management methods, nevertheless develop cystine peutically effective amount of a cystinase. stones (Chow and Streem, 1996). 0012 Another embodiment of the present invention is 0005. When cystine stone formation cannot be prevented directed to a method for lowering the concentration of using hydration, dietary restrictions and drug therapy, Sur cystine in a patient’s urine, comprising the step of admin gical management is necessary. Cystinuric patients often istering a therapeutically effective amount of a cystinase to have recurrent episodes of Stone formation and Surgeries in the patient. their lifetime. Shock wave lithotripsy, the use of high-energy 0013 In one embodiment of the present invention, the shock waves for Stone fragmentation, can be used for cystinase is cyStathionine B-lyase. treatment of cystine stones that are Smaller than 1.5 cm. Cystine Stones are the most Sturdy of all urinary stones and 0014. In another embodiment of the present invention, lithotripsy is generally ineffective in breaking them up. the cystinase is selected from the group consisting of cys However, Smaller cystine Stones may be fragmented with tothionine-gamma-lyase, cystine transaminase, cystine tran lithotripsy because more frequent shocks at higher energy shydrogenase, cystine reductase, cyStathionine B-lyase, and can be used. mixtures thereof. US 2006/0275.279 A1 Dec. 7, 2006 0015. In another embodiment of the present invention, tathionine to L-homocysteine in the biosynthesis of L-me the cystinase is covalently attached to a polymer. In one thionine (FIG. 1). This same enzyme has also been reported embodiment, that polymer is polyethylene glycol. to catalyze at a comparable rate an "un-natural reaction: the 0016. In still another embodiment of the present inven conversion of L-cystine into pyruvate, ammonia and thio tion, the cystinase is entrapped in a polymeric material. In cysteine, as shown in FIG. 2 (Dwivedi et al., 1982). Other one embodiment, that polymeric material comprises at least cystinases include cystothionine-gamma-lyase, cystine tran about 50% of a polylalkanoic acid, optionally polylactic saminase, cystine transhydrogenase, and cystine reductase. acid. Others will be apparent to those of skill in the art. 0027. Because of the high activity of cystinases toward 0017. In another embodiment of the present invention, cystine and the production of Soluble compounds upon its the cystinase is administered via a catheter into the kidney breakdown, these enzymes can be utilized for the dissolution of the patient. of cystine Stones in the kidneys through the use of a nephrostomy catheter in a manner similar to the chemodis BRIEF DESCRIPTION OF THE DRAWINGS solution method currently used. Thus, one embodiment of 0018. The patent or application file contains at least one the present invention is directed to the use of a cystinase for drawing executed in color. Copies of this patent or patent dissolution of cystine Stones in the kidneys. application publication with color drawings will be provided 0028 General Materials and Methods.
Load more

Recommended publications
  • Syntheses and Biological Activity of Sparsomycin and Analogs
    SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE ROB M.J. LISKAMP SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE Promotor : Prof. Dr. R.J.F. Nivard Co-referent : Dr. H.C.J. Ottenheijm SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE WISKUNDE EN NATUURWETENSCHAPPEN AAN DE KATHOLIEKE UNIVERSITEIT VAN NIJMEGEN OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. J.H.G.I. GIESBERS VOLGENS HET BESLUIT VAN HET COLLEGE VAN DEKANEN IN HET OPENBAAR TE VERDEDIGEN OP VRIJDAG 10 DECEMBER 1982 DES NAMIDDAGS OM 4 UUR DOOR ROBERTUS MATTHIAS JOSEPH LISKAMP GEBOREN TE NIJMEGEN NIJMEGEN 1982 Dit proefschrift vormt de neerslag van vier jaar wetenschappelijk onderzoek. Ik wil iedereen - en dat waren er zeer velen - bedanken, die hieraan gedurende die tijd door hun stimulerende discussie of door de feitelijke uitvoering deel hadden. Zij gaven mede richting en vorm, niet alleen organisch maar ook biochemisch/biologisch en fysisch chemisch, aan het verrichte onderzoek. Daarnaast wil ik hen bedanken die een bijdrage geleverd hebben aan de onmis­ bare technische uitvoering van het in dit proefschrift beschreven onderzoek. En tenslotte wil ik ook hen bedanken die aan de vormgeving van het proef­ schrift hun medewerking hebben verleend. Tekeningen : Wim van Luijn en de afdeling illustratie Type-werk : Dorine Hesselink-Balvert Afbeelding op de omslag: Een 'stacked plot' van een 2D-spin-echo correlated spectrum van synthetisch sparsomycine verzorgd door Wim Guijt This research was supported by the Netherlands Foundation for Chemical Research (SON) with financial aid from the Netherlands Organization for the Advancement of Pure Research (ZWO).
    [Show full text]
  • Biochemistry I Enzymes
    BIOCHEMISTRY I 3rd. Stage Lec. ENZYMES Biomedical Importance: Enzymes, which catalyze the biochemical reactions, are essential for life. They participate in the breakdown of nutrients to supply energy and chemical building blocks; the assembly of those building blocks into proteins, DNA, membranes, cells, and tissues; and the harnessing of energy to power cell motility, neural function, and muscle contraction. The vast majority of enzymes are proteins. Notable exceptions include ribosomal RNAs and a handful of RNA molecules imbued with endonuclease or nucleotide ligase activity known collectively as ribozymes. The ability to detect and to quantify the activity of specific enzymes in blood, other tissue fluids, or cell extracts provides information that complements the physician’s ability to diagnose and predict the prognosis of many diseases. Further medical applications include changes in the quantity or in the catalytic activity of key enzymes that can result from genetic defects, nutritional deficits, tissue damage, toxins, or infection by viral or bacterial pathogens (eg, Vibrio cholerae). Medical scientists address imbalances in enzyme activity by using pharmacologic agents to inhibit specific enzymes and are investigating gene therapy as a means to remedy deficits in enzyme level or function. In addition to serving as the catalysts for all metabolic processes, their impressive catalytic activity, substrate specificity, and stereospecificity enable enzymes to fulfill key roles in additional processes related to human health and well-being. Proteases and amylases augment the capacity of detergents to remove dirt and stains, and enzymes play important roles in producing or enhancing the nutrient value of food products for both humans and animals.
    [Show full text]
  • Phytochem Referenzsubstanzen
    High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.286. ABIETIC ACID Sylvic acid [514-10-3] 302.46 C20H30O2 01.030. L-ABRINE N-a-Methyl-L-tryptophan [526-31-8] 218.26 C12H14N2O2 Merck Index 11,5 01.031. (+)-ABSCISIC ACID [21293-29-8] 264.33 C15H20O4 Merck Index 11,6 01.032. (+/-)-ABSCISIC ACID ABA; Dormin [14375-45-2] 264.33 C15H20O4 Merck Index 11,6 01.002. ABSINTHIN Absinthiin, Absynthin [1362-42-1] 496,64 C30H40O6 Merck Index 12,8 01.033. ACACETIN 5,7-Dihydroxy-4'-methoxyflavone; Linarigenin [480-44-4] 284.28 C16H12O5 Merck Index 11,9 01.287. ACACETIN Apigenin-4´methylester [480-44-4] 284.28 C16H12O5 01.034. ACACETIN-7-NEOHESPERIDOSIDE Fortunellin [20633-93-6] 610.60 C28H32O14 01.035. ACACETIN-7-RUTINOSIDE Linarin [480-36-4] 592.57 C28H32O14 Merck Index 11,5376 01.036. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- a-D-Glucosamine pentaacetate 389.37 C16H23NO10 ACETYL-a-D-GLUCOPYRANOSE 01.037. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- b-D-Glucosamine pentaacetate [7772-79-4] 389.37 C16H23NO10 ACETYL-b-D-GLUCOPYRANOSE> 01.038. 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL- Acetochloro-a-D-glucosamine [3068-34-6] 365.77 C14H20ClNO8 a-D-GLUCOPYRANOSYLCHLORIDE - 1 - High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.039.
    [Show full text]
  • The Intracellular Ratio of Cysteine and Cystine in Various Tissues
    Biochem. J. (1967) 105, 891 891 Printed in Great Britain The Intracellular Ratio of Cysteine and Cystine in Various Tissues By J. C. CRAWHALL* AND S. SEGALt Clinical Endocrinology Branch, National In8titute of Arthriti8 and Metabolic Di8ease8, National Institute8 of Health, Bethe8da, Md., U.S.A. (Received 20 February 1967) 1. The cysteine-cystine ratio was measured in rat kidney cortex, diaphragm, jejunum, liver and brain. 2. This ratio was determined by incubating these tissues in buffer containing [35S]cystine and then homogenizing the tissue in a buffered solution of N-ethyhnaleimide. The products of this reaction were separated by high-voltage electrophoresis and the radioactivity in the cystine and 2-(L-2'-amino- 2'-carboxyethylthio)-N-ethylsuccinimide regions was determined. 3. In these tissues cyst(e)ine was mainly present in the reduced form. 4. After incubation of [35S]cystine with rat jejunal segments it was found that 36% of the cystine in the medium has been reduced. 5. Anaerobiosis, Na+-free media, glucose and high concentrations of cystine and lysine were found not to affect significantly the cysteine-cystine ratio in rat kidney-cortex slices. Numerous studies of the kinetics of amino acid The method of measuring cystine-cysteine ratios transport into various tissues in vitro have been described in this paper has been designed to remove described. One of the requirements of this type of all the cellular enzyme activity as rapidly as study with radioactive isotopically labelled amino possible at the end ofthe tissue incubation period by acids is that the radioactivity measured within the precipitation of the enzymes with trichloroacetic tissue corresponds to the amino acid being studied acid.
    [Show full text]
  • The Cysteine Proteome 13 N Q114 Young-Mi Go, Joshua D
    Free Radical Biology and Medicine ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 1 Contents lists available at ScienceDirect 2 3 4 Free Radical Biology and Medicine 5 6 journal homepage: www.elsevier.com/locate/freeradbiomed 7 8 9 Review Article 10 11 12 The cysteine proteome 13 n Q114 Young-Mi Go, Joshua D. Chandler, Dean P. Jones 15 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University, Atlanta, GA 30322, USA 16 17 18 article info abstract 19 20 Article history: The cysteine (Cys) proteome is a major component of the adaptive interface between the genome and 21 Received 17 November 2014 the exposome. The thiol moiety of Cys undergoes a range of biologic modifications enabling biological 22 Received in revised form switching of structure and reactivity. These biological modifications include sulfenylation and disulfide 23 17 March 2015 formation, formation of higher oxidation states, S-nitrosylation, persulfidation, metalation, and other Accepted 22 March 2015 24 modifications. Extensive knowledge about these systems and their compartmentalization now provides 25 a foundation to develop advanced integrative models of Cys proteome regulation. In particular, detailed Keywords: 26 understanding of redox signaling pathways and sensing networks is becoming available to allow the Cysteine proteome discrimination of network structures. This research focuses attention on the need for atlases of Cys 27 Redox proteome modifications to develop systems biology models. Such atlases will be especially useful for integrative 28 Redox signaling studies linking the Cys proteome to imaging and other omics platforms, providing a basis for improved 29 Functional network Thiol redox-based therapeutics. Thus, a framework is emerging to place the Cys proteome as a complement to 30 Free radicals the quantitative proteome in the omics continuum connecting the genome to the exposome.
    [Show full text]
  • Metabolic Regulation of Ferroptosis in Cancer
    biology Review Metabolic Regulation of Ferroptosis in Cancer Min Ji Kim 1,2,† , Greg Jiho Yun 1,2,† and Sung Eun Kim 1,2,* 1 Department of Biosystems and Biomedical Sciences, College of Health Sciences, Korea University, Seoul 305-350, Korea; [email protected] (M.J.K.); [email protected] (G.J.Y.) 2 Department of Integrated Biomedical and Life Sciences, College of Health Sciences, Korea University, Seoul 305-350, Korea * Correspondence: [email protected]; Tel.: +82-2-3290-5647 † These authors contributed equally to this work as co-first authors. Simple Summary: Ferroptosis is a recently defined nonapoptotic form of cell death that is associated with various human diseases, including cancer. As ferroptosis is caused by an overdose of lipid peroxidation resulting from dysregulation of the cellular antioxidant system, it is inherently closely associated with cellular metabolism. Here, we provide an updated review of the recent studies that have shown mechanisms of metabolic regulation of ferroptosis in the context of cancer. Abstract: Ferroptosis is a unique cell death mechanism that is executed by the excessive accumulation of lipid peroxidation in cells. The relevance of ferroptosis in multiple human diseases such as neurodegeneration, organ damage, and cancer is becoming increasingly evident. As ferroptosis is deeply intertwined with metabolic pathways such as iron, cyst(e)ine, glutathione, and lipid metabolism, a better understanding of how ferroptosis is regulated by these pathways will enable the precise utilization or prevention of ferroptosis for therapeutic uses. In this review, we present an update of the mechanisms underlying diverse metabolic pathways that can regulate ferroptosis in cancer.
    [Show full text]
  • Molecular Basis for Redox Control by the Human Cystine/Glutamate Antiporter
    bioRxiv preprint doi: https://doi.org/10.1101/2021.08.09.455631; this version posted August 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Molecular basis for redox control by the human cystine/glutamate antiporter System xc-. Joanne L. Parker1, *, #, Justin C. Deme2,3,4#, Dimitrios Kolokouris1, Gabriel Kuteyi1, Philip C. Biggin1, Susan M. Lea2,3,4 *, Simon Newstead1,5*. 1Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK; 2Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, 3 Central Oxford Structural Molecular Imaging Centre, University of Oxford, South Parks Road, Oxford, OX1 3RE, 4Center for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA, 5The Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK. Cysteine plays an essential role in cellular redox homeostasis as a key constituent of the tripeptide glutathione (GSH). A rate limiting step in cellular GSH synthesis is the availability of cysteine. However, circulating cysteine exists in the blood as the oxidised di-peptide cystine, requiring specialised transport systems for its import into the cell. System xc- is a dedicated cystine transporter, importing cystine in exchange for intracellular glutamate. To counteract elevated levels of reactive oxygen species in cancerous cells system xc- is frequently upregulated, making it an attractive target for anticancer therapies. However, the molecular basis for ligand recognition remains elusive, hampering efforts to specifically target this transport system.
    [Show full text]
  • O O2 Enzymes Available from Sigma Enzymes Available from Sigma
    COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc.
    [Show full text]
  • Copyrighted Material
    Index Abhexon, 501, 565 bitter, 636 reactions, 564, 565 dimethylarsinoyl, 415 Abietadiene, 505, 506 oxocarboxylic, 550 Abietic acid, 189 phenolic, 551 Absinthin, 634 reactions, 555 Acacetin, 695 sugar, 212 Acacipetalin, 775, 776 Acidulants, 872 Acenaphthene, 919 Aconitic acid, 546 Acenaphthylene, 919 Acorin, 635 Acephate, 1010 Acrolein, 82 Aceric acid, 213, 214, 259 reactions, 180, 181, 193, 527, 538 Acesulfame K, 865, 866, 870 Acromelic acids, 829 Acetaldehyde, 72, 527 Acrylamide, 899, 900 reactions, 295, 538, 540 content in foods, 900 Acetals, 537, 541 reactions, 901, 902 reactions, 538 Acrylic acid, 1034 Acetic acid, 542, 850 Acrylonitrile, 1039 reactions, 296, 297, 543 Actin, 47 Acetoacetic acid, 551 Actinin, 47 Acetoin, 522, 536 Acylchloropropanediols, 910 reactions, 522 Acyloins, 536 Acetol, see hydroxyacetone Acylsphingosines, see ceramides Acetone, 533 Additives, 847 reactions, 540 Adenine, 396, 397 Acetophenone, 535 Adenosine diphosphate, see ADP Acetylcholine, 399 monophosphate, see AMP Acetylcysteines, see mercapturates triphosphate, see ATP Acetylfuran, 286 Adenylic acid, see AMP Acetylgalactosamine, 53, 58 Adermine, see vitamin B6 Acetylglucosamine, 58 Adhesives, 889 Acetylhistidines, 20 Adhyperflorin, 712 Acetyllactaminic acid, see acetylneuraminic acid Adipic acid, 544 Acetyllysine, 18 ADP, 18, 874 Acetylmuramic acid, 217 Adrastin, 951 Acetylneuraminic acid, 53, 58, 217 COPYRIGHTEDAdrenaline, MATERIALsee epinephrine Acetylpyridine, 590 Adriatoxin, 838 Acetylpyrroline, 18, 501 Advanced glycation end products, 319–23 Acetylpyrroline, reactions, 599 lipoxidation end products, 319 Acetyltetrahydropyridine, 18 Aflatoxicol, 946 Acetyltetrahydropyridine, reactions, 600 Aflatoxins, 942, 945–8 Acids as preservatives, 848 Aflatrem, 961 lipoamino, 129 Afzelechins, 648 aldonic, 212 Agar, 269 alicyclic, 551 Agaric acid, see agaricinic acid aromatic, 551 Agaricinic acid, 835, 865 bile, 140 Agaricone, 705 The Chemistry of Food, First Edition.
    [Show full text]
  • Redox Homeostatis and Stress in Mouse Livers Lacking the Nadph
    REDOX HOMEOSTASIS AND STRESS IN MOUSE LIVERS LACKING THE NADPH-DEPENDENT DISULFIDE REDUCTASE SYSTEMS by Colin Gregory Miller A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Chemistry MONTANA STATE UNIVERSITY Bozeman, Montana November 2019 ©COPYRIGHT by Colin Gregory Miller 2019 All Rights Reserved ii DEDICATION I would like to dedicate this thesis to my dear friends Adrienne Arnold, Jacob Artz, Aoife Casey, Michael Christman, Phil Hartman, Ky Mickelsen, Sarah Partovi, Greg Prussia and Danica Walsh. Your support has been indescribably generous and completely invaluable. My quality of life, especially during graduate school, has been immeasurably improved by you all and I count myself incredibly lucky to call you my friends and colleagues. Most importantly, I would like to dedicate this degree to my mom. Any standard of excellence I have ever held has been inspired by you. Your compassion and generosity to others, your unwavering positivity and resilience are a constant source of inspiration. I would consider myself a complete success if I grow up to be half the person you are. iii ACKNOWLEDGEMENTS First, I would like to acknowledge support for the work presented in this thesis provided by the NIH (AG055022) and Montana State University. I would also like to acknowledge committee members Dr. Mary Cloninger and Dr. Brian Bothner for invaluable scientific support and guidance. I would like to thank Dr. Loretta Dorn, Dr. James Hohman and the Chemistry Department of Fort Hays State University for providing me the training and desire to pursue a life in science.
    [Show full text]
  • Cysteine: an Overlooked Energy and Carbon Source
    www.nature.com/scientificreports OPEN Cysteine: an overlooked energy and carbon source Luise Göbbels1, Anja Poehlein2, Albert Dumnitch1, Richard Egelkamp2, Cathrin Kröger1, Johanna Haerdter3, Thomas Hackl3, Artur Feld4, Horst Weller4, Rolf Daniel2, Wolfgang R. Streit1 & Marie Charlotte Schoelmerich1* Biohybrids composed of microorganisms and nanoparticles have emerged as potential systems for bioenergy and high-value compound production from CO2 and light energy, yet the cellular and metabolic processes within the biological component of this system are still elusive. Here we dissect the biohybrid composed of the anaerobic acetogenic bacterium Moorella thermoacetica and cadmium sulphide nanoparticles (CdS) in terms of physiology, metabolism, enzymatics and transcriptomic profling. Our analyses show that while the organism does not grow on l-cysteine, it is metabolized to acetate in the biohybrid system and this metabolism is independent of CdS or light. CdS cells have higher metabolic activity, despite an inhibitory efect of Cd2+ on key enzymes, because of an intracellular storage compound linked to arginine metabolism. We identify diferent routes how cysteine and its oxidized form can be innately metabolized by the model acetogen and what intracellular mechanisms are triggered by cysteine, cadmium or blue light. Anaerobic microorganisms play a pivotal role in the global cycling of elements and nutrients, are key in determin- ing the health of animals and humans and are important players for biotechnological and industrial processes to solve tomorrow’s challenges of pollution, resource scarcity and energy requirements 1,2. An innovative proof-of- concept study has recently been described in which a non-photosynthetic anaerobic bacterium becomes photo- synthetic by coupling it to CdS nanoparticles3.
    [Show full text]
  • Molecular Mechanism and Metabolic Function of the S
    MOLECULAR MECHANISM AND METABOLIC FUNCTION OF THE S- NITROSO-COENZYME A REDUCTASE AKR1A1 by COLIN T. STOMBERSKI Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Jonathan S. Stamler Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY May, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of COLIN T. STOMBERSKI candidate for the degree of Doctor of Philosophy*. Committee Chair Focco van den Akker Committee Members Jonathan Stamler George Dubyak Mukesh Jain Hung-Ying Kao 03-22-2019 *We also certify that written approval has been obtained for any proprietary material contained therein TABLE OF CONTENTS Table of Contents ………………………………………………………………………… i List of Tables ……………………………………………………………………………. v List of Figures ………………………………………………………………………….. vi List of Abbreviations …………………………………………………………………… ix Acknowledgements …………………………………………………………………….. xi Abstract ………………………………………………………………………………….. 1 Foundation and Experimental Framework ……………………………………………….. 3 Chapter 1: Protein S-nitrosylation: Determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling …………………………………………….. 5 1.1 Introduction …………………………………………………………………. 6 1.2 S-nitrosothiol specificity …………………………………………………….. 8 1.2.1 Acid-base and hydrophobic motifs ……………………………… 9 1.2.2 Interaction with nitric oxide synthases ………………………….. 13 1.3 S-nitrosothiol stability and reactivity ……………………………………….. 15 1.3.1 RSNO bond chemistry ………………………………………….. 16 1.3.2 Protein SNO—thiol reaction bias ………………………………. 18 1.3.3 SNO sites do not overlap S-oxidation sites …………………….. 19 1.4 Enzymatic denitrosylation ………………………………………………….. 20 1.4.1 The thioredoxin system ………………………………………… 21 1.4.2 LMW-SNO reductases …………………………………………. 23 1.4.3 The GSNO reductase system …………………………………… 24 1.4.4 GSNOR in physiology and pathophysiology …………………… 26 i 1.4.5 The SNO-CoA reductase system ……………………………….. 31 1.5 Specificity in denitrosylation ……………………………………………….
    [Show full text]